Cytosorbents (CTSO) Return on Capital Employed Growth (3y) (2014 - 2026)
Cytosorbents (CTSO) Return on Capital Employed Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -1,679.00 |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 214.00 |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 145.00 |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 355.00 |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -846.00 |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 1,318.00 |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -247.00 |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | - |
| 10 | Cytosorbents | 23.04 Mn | 18.24 Mn | 6.13 Mn | 879.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 879.00 |
| Dec 31, 2025 | 1,760.00 |
| Sep 30, 2025 | 2,390.00 |
| Jun 30, 2025 | 689.00 |
| Mar 31, 2025 | -127.00 |
| Dec 31, 2024 | -1,463.00 |
| Sep 30, 2024 | -3,458.00 |
| Jun 30, 2024 | -4,645.00 |
| Mar 31, 2024 | -6,141.00 |
| Dec 31, 2023 | -7,422.00 |
| Sep 30, 2023 | -5,128.00 |
| Jun 30, 2023 | -1,215.00 |
| Mar 31, 2023 | 840.00 |
| Dec 31, 2022 | 4,542.00 |
| Sep 30, 2022 | 3,787.00 |
| Jun 30, 2022 | 2,438.00 |
| Mar 31, 2022 | 2,619.00 |
| Dec 31, 2021 | 2,814.00 |
| Sep 30, 2021 | 2,702.00 |
| Jun 30, 2021 | 3,199.00 |